

9th March, 2016

The Dy. General Manager (Listing Dept.)
BSE Limited.,
Corporate Relationship Dept.,
1st Floor, New Trading Ring,
P. J. Towers, Dalal Street, Fort,
Mumbai - 400 001
(BSE Scrip Code: 500420)

✓ The Manager – Listing Dept.,
National Stock Exchange of India Ltd.,
Exchange Plaza, 5th Floor,
Plot No. C/1, G. Block,
Bandra - Kurla Complex, Bandra (E),
Mumbai – 400 051
(NSE Scrip Code: TORNTPHARM)

Dear Sir,

Sub.: Intimation under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), 2015, regarding declaration of Second Interim Dividend and pay out date.

We would like to inform you that the Board of Directors in its meeting held on Wednesday, 9th March, 2016 has approved the payment of a special dividend as second interim dividend of `15 (300%) per equity share of ` 5/- each fully paid up.

The Board Meeting commenced at 10:00 AM and concluded at 10:45AM.

The above is in continuation of our letter dated 3rd March, 2016 intimating about the said Board Meeting.

The dividend is expected to be paid / dispatched on or around 23rd March, 2016.


A press release on the declaration of the dividend is enclosed herewith.

Kindly take note of the same.

Thanking you,

Yours Sincerely,

For TORRENT PHARMACEUTICALS LIMITED



MAHESH AGRAWAL
VP (LEGAL) & COMPANY SECRETARY

Encl: As above

TORRENT PHARMACEUTICALS LIMITED

CIN : L24230GJ1972PLC002126

Reg. Office : Torrent House, Off Ashram Road, Ahmedabad - 380 009, India. Phone: +91 79 26585090 www.torrentpharma.com



Torrent Pharma declares Second Interim Dividend of 300% (Rs. 15 per share)

March 9th 2016

Ahmedabad based Pharmaceuticals major, Torrent Pharmaceuticals Limited, today declared a special dividend as the second interim dividend of 300% (Rs.15 per Share).

The Company has earned an exceptional profit on account of lower than anticipated competition in one of its products being marketed in US, which may not be sustainable. The Board considered distributing a part of the exceptional profit on account of this and other one off items, as a special dividend, while at the same time retaining sufficient funds for the investment plans of the Company.

The Company continues to invest for building future capabilities. After the slated completion of the first phase of its Dahej manufacturing facility, the work on the second phase is likely to start in near future. This is in addition to significant investments being planned in augmenting capacities at other plants.

About Torrent Pharma

Torrent Pharma, with annual revenues of almost Rs. 4700 crores is the flagship Company of the Torrent Group. Torrent continues to be at the forefront of the Indian pharmaceutical industry with many of its products ranking among the top 500 brands (AIOCD Dataset).

Torrent has a full equipped Research Center, employing almost 600 scientists, to support the Company's operations and product pipeline for both Domestic and Overseas markets. The Company's manufacturing plants located at Indrad, Baddi & Sikkim have facilities to produce Formulations and Bulk drugs. The plants are approved by authorities from various regulated and semi regulated markets like US, UK, Brazil, Germany, Australia and South Africa.

